Profiles Research Networking Software The University of Chicago
Keywords
Last Name
Institution

SAMUEL L. VOLCHENBOUM

TitleASSISTANT PROFESSOR     
InstitutionUniversity of Chicago
DepartmentPEDIATRICS
AddressChicago IL 60637

 Overview 
 overview
Samuel Volchenboum is a physician who treats pediatric cancers and blood disorders, with a specialization in treating children with neuroblastoma and other pediatric solid tumors. His research explores the use of computation to define diseases in greater detail. His discoveries in genetics could lead to personalized and targeted therapies with better outcomes and fewer side effects in children as well as adults.

As a researcher and physician, Volchenboum serves as an assistant professor in the Department of Pediatrics. His research methodologies include using proteomics to study pediatric solid tumors and building tools for high-throughput mass spectrometry data analysis.

His lab has a number of outside collaborations, including an international multi-institutional effort to establish a database for neuroblastoma patient data. He also works with the Children’s Hospital of Philadelphia to study the effects of TrkA and TrkB signaling in neuroblastoma cell lines.

Volchenboum is the of the BSD Center for Research Informatics. He also is the associate director of the Institute for Translational Medicine, Associate Chief Research Informatics Officer, and a fellow and faculty member of the Computation Institute.

Volchenboum has been on the UChicago faculty since 2007, and in 2009 he was named a St. Baldrick's Foundation Scholar. Volchenboum received his PhD in molecular biology and MD from the Mayo Medical School. He completed his residency at Cincinnati Children’s Hospital Medical Center before going to Boston for his pediatric hematology/oncology fellowship at the Dana-Farber Cancer Institute and Boston Children’s Hospital. He also completed a fellowship in informatics and received his Master’s in biomedical informatics from the Massachusetts Institute of Technology.


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Volchenboum SL, Mayampurath A, Göksu-Gürsoy G, Edelson DP, Howell MD, Churpek MM. Association Between In-Hospital Critical Illness Events and Outcomes in Patients on the Same Ward. JAMA. 2016 12 27; 316(24):2674-2675.
    View in: PubMed
  2. Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, Pinto N, Volchenboum SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 Feb; 72:177-185.
    View in: PubMed
  3. Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 Dec; 6(12):1342-1351.
    View in: PubMed
  4. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016 Sep; 65:1-10.
    View in: PubMed
  5. Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56.
    View in: PubMed
  6. Bagatell R, McHugh K, Naranjo A, Van Ryn C, Kirby C, Brock P, Lyons KA, States LJ, Rojas Y, Miller A, Volchenboum SL, Simon T, Krug B, Sarnacki S, Valteau-Couanet D, von Schweinitz D, Kammer B, Granata C, Pio L, Park JR, Nuchtern J. Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study. J Clin Oncol. 2016 Mar 01; 34(7):740-6.
    View in: PubMed
  7. Padula WV, Blackshaw L, Brindle CT, Volchenboum SL. An Approach to Acquiring, Normalizing, and Managing EHR Data From a Clinical Data Repository for Studying Pressure Ulcer Outcomes. J Wound Ostomy Continence Nurs. 2016 Jan-Feb; 43(1):39-45.
    View in: PubMed
  8. Rosebeck S, Alonge MM, Kandarpa M, Mayampurath A, Volchenboum SL, Jasielec J, Dytfeld D, Maxwell SP, Kraftson SJ, McCauley D, Shacham S, Kauffman M, Jakubowiak AJ. Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor. Mol Cancer Ther. 2016 Jan; 15(1):60-71.
    View in: PubMed
  9. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20; 33(27):3008-17.
    View in: PubMed
  10. Bao R, Hernandez K, Huang L, Kang W, Bartom E, Onel K, Volchenboum S, Andrade J. ExScalibur: A High-Performance Cloud-Enabled Suite for Whole Exome Germline and Somatic Mutation Identification. PLoS One. 2015; 10(8):e0135800.
    View in: PubMed
  11. Volchenboum SL, Andrade J, Huang L, Barkauskas DA, Krailo M, Womer RB, Ranft A, Potratz J, Dirksen U, Triche TJ, Lawlor ER. Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group. J Pathol Clin Res. 2015 Apr; 1(2):83-94.
    View in: PubMed
  12. Dytfeld D, Rosebeck S, Kandarpa M, Mayampurath A, Mellacheruvu D, Alonge MM, Ngoka L, Jasielec J, Richardson PG, Volchenboum S, Nesvizhskii AI, Sreekumar A, Jakubowiak AJ. Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. Br J Haematol. 2015 Jul; 170(1):66-79.
    View in: PubMed
  13. Hu Y, Mayampurath A, Khan S, Cohen JK, Mechref Y, Volchenboum SL. N-linked glycan profiling in neuroblastoma cell lines. J Proteome Res. 2015 May 01; 14(5):2074-81.
    View in: PubMed
  14. Truman AW, Kristjansdottir K, Wolfgeher D, Ricco N, Mayampurath A, Volchenboum SL, Clotet J, Kron SJ. The quantitative changes in the yeast Hsp70 and Hsp90 interactomes upon DNA damage. Data Brief. 2015 Mar; 2:12-5.
    View in: PubMed
  15. Truman AW, Kristjansdottir K, Wolfgeher D, Ricco N, Mayampurath A, Volchenboum SL, Clotet J, Kron SJ. Quantitative proteomics of the yeast Hsp70/Hsp90 interactomes during DNA damage reveal chaperone-dependent regulation of ribonucleotide reductase. J Proteomics. 2015 Jan 01; 112:285-300.
    View in: PubMed
  16. Applebaum MA, Henderson TO, Lee SM, Pinto N, Volchenboum SL, Cohn SL. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer. 2015 Jan; 62(1):128-33.
    View in: PubMed
  17. Kho AN, Hynes DM, Goel S, Solomonides AE, Price R, Hota B, Sims SA, Bahroos N, Angulo F, Trick WE, Tarlov E, Rachman FD, Hamilton A, Kaleba EO, Badlani S, Volchenboum SL, Silverstein JC, Tobin JN, Schwartz MA, Levine D, Wong JB, Kennedy RH, Krishnan JA, Meltzer DO, Collins JM, Mazany T. CAPriCORN: Chicago Area Patient-Centered Outcomes Research Network. J Am Med Inform Assoc. 2014 Jul-Aug; 21(4):607-11.
    View in: PubMed
  18. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Hero B, Di Cataldo A, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson AD, Irwin MS. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. J Clin Oncol. 2014 Apr 20; 32(12):1228-35.
    View in: PubMed
  19. Wilson RA, Teng L, Bachmeyer KM, Bissonnette ML, Husain AN, Parham DM, Triche TJ, Wing MR, Gastier-Foster JM, Barr FG, Hawkins DS, Anderson JR, Skapek SX, Volchenboum SL. A novel algorithm for simplification of complex gene classifiers in cancer. Cancer Res. 2013 Sep 15; 73(18):5625-32.
    View in: PubMed
  20. Mandal S, Baron BW, Mischeaux M, James K, Roig J, Landers J, Volchenboum SL, Cunningham JM, Reardon B, Musa G, Richa EM. Collection of peripheral blood stem cells from a 7 month-old girl weighing 7 kg with the use of combined heparin and citrate anticoagulation. J Clin Apher. 2013 Aug; 28(4):309-10.
    View in: PubMed
  21. Wang W, Zhong Q, Teng L, Bhatnagar N, Sharma B, Zhang X, Luther W, Haynes LP, Burgoyne RD, Vidal M, Volchenboum S, Hill DE, George RE. Mutations that disrupt PHOXB interaction with the neuronal calcium sensor HPCAL1 impede cellular differentiation in neuroblastoma. Oncogene. 2014 Jun 19; 33(25):3316-24.
    View in: PubMed
  22. Kirby C, Ambros PF, Billiter D, London WB, Mendonca E, Monclair T, Pearson AD, Cohn SL, Volchenboum SL. Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaboration. AMIA Jt Summits Transl Sci Proc. 2013; 2013:103.
    View in: PubMed
  23. Morales La Madrid A, Volchenboum S, Gastier-Foster JM, Pyatt R, Liu D, Pytel P, Lavarino C, Rodriguez E, Cohn SL. Locoregional MYCN-amplified neuroblastoma. Pediatr Blood Cancer. 2012 Oct; 59(4):736-8.
    View in: PubMed
  24. Lu Z, Cheng Z, Zhao Y, Volchenboum SL. Bioinformatic analysis and post-translational modification crosstalk prediction of lysine acetylation. PLoS One. 2011; 6(12):e28228.
    View in: PubMed
  25. McNerney ME, Baron BW, Volchenboum SL, Papari M, Keith M, Williams K, Richa E. Development of warm auto- and allo-antibodies in a 3-year old boy with sickle cell haemoglobinopathy following his first transfusion of a single unit of red blood cells. Blood Transfus. 2010 Apr; 8(2):126-8.
    View in: PubMed
  26. Volchenboum SL, Cohn SL. Are molecular neuroblastoma classifiers ready for prime time? Lancet Oncol. 2009 Jul; 10(7):641-2.
    View in: PubMed
  27. Volchenboum SL, Li C, Li S, Attiyeh EF, Reynolds CP, Maris JM, Look AT, George RE. Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Res. 2009 May 15; 69(10):4143-9.
    View in: PubMed
  28. Volchenboum SL, Kristjansdottir K, Wolfgeher D, Kron SJ. Rapid validation of Mascot search results via stable isotope labeling, pair picking, and deconvolution of fragmentation patterns. Mol Cell Proteomics. 2009 Aug; 8(8):2011-22.
    View in: PubMed
  29. Volchenboum SL, Cohn SL. Progress in defining and treating high-risk neuroblastoma: lessons from the bench and bedside. J Clin Oncol. 2009 Mar 01; 27(7):1003-4.
    View in: PubMed
  30. Hartford C, Volchenboum SL, Cohn SL. 3 + 3 not equal to (Rolling) 6. J Clin Oncol. 2008 Jan 10; 26(2):170-1.
    View in: PubMed
  31. Volchenboum SL, Mohsen AW, Kim JJ, Vockley J. Arginine 387 of human isovaleryl-CoA dehydrogenase plays a crucial role in substrate/product binding. Mol Genet Metab. 2001 Sep-Oct; 74(1-2):226-37.
    View in: PubMed
  32. Volchenboum SL, Vockley J. Mitochondrial import and processing of wild type and type III mutant isovaleryl-CoA dehydrogenase. J Biol Chem. 2000 Mar 17; 275(11):7958-63.
    View in: PubMed
  33. Mohsen AW, Anderson BD, Volchenboum SL, Battaile KP, Tiffany K, Roberts D, Kim JJ, Vockley J. Characterization of molecular defects in isovaleryl-CoA dehydrogenase in patients with isovaleric acidemia. Biochemistry. 1998 Jul 14; 37(28):10325-35.
    View in: PubMed
VOLCHENBOUM's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_